Skip to main content
Premium Trial:

Request an Annual Quote

DNA Manufacturer OriCiro Genomics Raises ¥800M in Series B Round

NEW YORK — OriCiro Genomics, a Japanese manufacturer of DNA for therapeutic and synthetic biology applications, said on Tuesday that it has raised ¥800 million ($7.3 million) in Series B funding and secured a ¥200 million long-term loan.

The financing round was led by University of Tokyo Edge Capital Partners and included ITOCHU Technology Ventures. The loan was provided by Japan Finance, a government-affiliated financial institution.

OriCiro was founded in late 2018 to develop and commercialize a proprietary technology for the cell-free assembly and amplification of large circular DNA. The so-called OriCiro Cell-Free Cloning System has applications in the pharmaceutical, diagnostic, agriculture, and food industries, according to the Tokyo-based company.

OriCiro said it will use the proceeds of the Series B round and loan to expand its manufacturing capabilities, advance its R&D, establish a US subsidiary, expand its intellectual property estate, and bring on new hires. It is also planning to launch a new plasmid DNA supply business aimed at the pharmaceutical and drug discovery markets.

The Scan

Taking Stock of the Stockpile

The US and European countries are evaluating their smallpox vaccine stockpiles as the number of monkeypox cases increases, the Washington Post reports.

Vitamin D From Tomatoes

According to Reuters, researchers in the UK have gene-edited tomatoes so their fruit contains vitamin D.

Cause Not Yet Spotted

NPR reports that a new study was unable to find a cause for persistent long COVID symptoms.

PNAS Papers on Central African Hunter-Gatherers, Myopia Development, Ancient Microtia Allele

In PNAS this week: population patterns among Central African hunter gatherers, effect of myopia-linked gene variant, and more.